Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.50

    ▲ 1.44 (13.02%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ 0.04 (8.89%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Medigene — 2 videos in collection

More on this equity

Medigene is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with the aim of effectively eliminating cancer.

Medigene hosted an R&D event on its 3S (specific, sensitive and safe) T cell receptors (TCRs), designed for precision immunotherapies. Management highlighted the versatility of these TCRs across TCR-engineered T cell (TCR-T) therapies, TCR-guided T cell engager (TCR-TCE) therapies and TCR-natural killer cell (TCR-NK) therapies. Dr David Zhen outlined the MDG1015 lead program, showcasing its novel approach to treating solid tumours. The webinar also highlighted Medigene’s end-to-end platform, which combines multiple modular technologies for developing diverse TCR-guided therapies.

< Previous
Next >

You may also be interested in these:

Healthcare

Medigene – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free